Monitoring withdrawal symptoms in newborns exposed to opioids.
Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.
['FUNDING_SBIR_2'] · REKOVAR INC. · NIH-10986010
This study is working on a new, easy-to-use wireless system that helps doctors keep an eye on babies going through withdrawal from opioids, using comfortable wearable devices to track their heart rate and other signs, so they can provide better care.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | REKOVAR INC. (nih funded) |
| Locations | 1 site (Lake Forest, UNITED STATES) |
| Trial ID | NIH-10986010 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a wireless system to detect and monitor withdrawal symptoms in newborns suffering from neonatal abstinence syndrome (NAS), which occurs when infants are exposed to opioids in utero. The approach involves using flexible, low-cost wearable devices that can continuously measure physiological responses such as heart rate and skin conductance. By providing objective data on the severity of NAS, this system aims to improve the accuracy of diagnosis and treatment monitoring, reducing reliance on subjective assessments by healthcare providers.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborns diagnosed with neonatal abstinence syndrome due to in utero opioid exposure.
Not a fit: Patients who are not newborns or those who have not been exposed to opioids in utero may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer management of withdrawal symptoms in newborns, potentially reducing hospital stays and associated healthcare costs.
How similar studies have performed: While the use of wearable technology for monitoring physiological responses is gaining traction, this specific application for neonatal abstinence syndrome is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Lake Forest, UNITED STATES
- REKOVAR INC. — Lake Forest, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHARAREH, SHIVA — REKOVAR INC.
- Study coordinator: SHARAREH, SHIVA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.